Search results for "Original article"

showing 10 items of 1187 documents

A particular phenotype of ascending aorta aneurysms as precursor of type A aortic dissection.

2012

Objectives: We aimed to identify a phenotype of ascending thoracic aortic aneurysm (TAA), which, more than others, evolves into type A dissection (TAD). Methods: Aortic specimens were obtained from patients undergoing surgical repair of TAA and TAD (108 and 26, respectively). Histopathological and immunohistochemical analyses were performed by using adequate tissue specimens, appropriate techniques and criteria. Results: We identified the three following TAA phenotypes: phenotype I (cystic medial degeneration balanced by a substitutive fibrosis, in absence of medial apoptosis and with a faint collagenase concentration), phenotype II (cystic medial degeneration of higher grade, respectively,…

Pulmonary and Respiratory MedicineMalePathologymedicine.medical_specialtyAorta ThoracicApoptosisThoracic aortic aneurysmAortic aneurysmAneurysmFibrosismedicine.arteryAscending aortamedicineSettore MED/05 - Patologia ClinicaThoracic aortaHumansAgedAortic dissectionAortaAortic Aneurysm Thoracicbusiness.industryDissectionSettore MED/23 - Chirurgia CardiacaOriginal ArticlesMiddle Agedmedicine.diseasePrognosisAneurysmFibrosisImmunohistochemistryAortic DissectionPhenotypeMatrix Metalloproteinase 9Disease ProgressionSurgeryFemaleThoracic aortic aneurysm phenotype IIICardiology and Cardiovascular MedicinebusinessAneurysm ; Dissection ; Thoracic aortic aneurysm phenotype IIIBiomarkersInteractive cardiovascular and thoracic surgery
researchProduct

Secondary Carina and Lobar Bronchi Stenting in Patients with Advanced Lung Cancer: Is It Worth the Effort? A Clinical Experience

2020

Background: The lobar airway stenting remains an endoscopic procedure not well standardized in patients with locally advanced lung cancer disease. The goal of this study was to evaluate technical feasibility, clinical outcome, and complications of different stents in patients with malignant lesions involving lobar bronchi, primary and secondary carina. Methods: Between November 2008 and October 2013, we retrospectively analyzed 146 patients with benign and malignant tracheobronchial stenosis who underwent airway stent insertion below main carina and main bronchi. Results: In all, 170 airway stenting procedures were performed on 146 patients. In all, 51 of them with malignant peripheral airw…

Pulmonary and Respiratory MedicineMalemedicine.medical_specialtyLung Neoplasmsmedicine.medical_treatmentSettore MED/21 - Chirurgia ToracicaBronchiairway stentingBronchoscopymedicineHumansIn patientLung cancerAgedRetrospective StudiesAged 80 and overLungmedicine.diagnostic_testbusiness.industryPalliative CareGastroenterologyStentGranulation tissueGeneral Medicinerespiratory systemMiddle Agedmedicine.diseaseequipment and suppliesrespiratory tract diseasesAirway ObstructionStenosislung cancermedicine.anatomical_structureTreatment Outcomeairway stenosisFeasibility StudiesSurgeryFemaleStentsOriginal ArticleRadiologyCardiology and Cardiovascular MedicineAirwayChest radiographbusinessTracheal Stenosis
researchProduct

Noninvasive ventilation during the weaning process in chronically critically ill patients.

2016

Chronically critically ill patients often undergo prolonged mechanical ventilation. The role of noninvasive ventilation (NIV) during weaning of these patients remains unclear. The aim of this study was to determine the value of NIV and whether a parameter can predict the need for NIV in chronically critically ill patients during the weaning process. We conducted a prospective study that included chronically critically ill patients admitted to Spanish respiratory care units. The weaning method used consisted of progressive periods of spontaneous breathing trials. Patients were transferred to NIV when it proved impossible to increase the duration of spontaneous breathing trials beyond 18 h. 2…

Pulmonary and Respiratory MedicineMechanical ventilationmedicine.medical_specialty8business.industryCritically illmedicine.medical_treatmentlcsh:Rlcsh:Medicine030208 emergency & critical care medicineOriginal Articles03 medical and health sciences0302 clinical medicine030228 respiratory systemBreathingMedicineWeaningmedicine.symptombusinessIntensive care medicineProspective cohort studyRespiratory Care UnitsHypercapniaRespiratory careERJ open research
researchProduct

Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancérologie Thoracique Biomarkers France Study by KRAS Mutation Subtypes

2020

Abstract Introduction KRAS mutations are detected in 20% to 30% of NSCLC. However, KRAS mutation subtypes may differently influence the outcome of patients with advanced NSCLC. Methods In the Biomarkers France study, 4894 KRAS mutations (26.2%) were detected in 4634 patients from the 17,664 enrolled patients with NSCLC. Survival and treatment data on noncurative stage III to IV NSCLC were available for 901 patients. First- and second-line treatment effects on progression-free survival and overall survival were analyzed according to the KRAS mutations subtype. Results Over 95% of patients with KRAS mutation were smokers or former smokers who were white (99.5%), presenting with adenocarcinoma…

Pulmonary and Respiratory MedicineOncologymedicine.medical_specialtyendocrine system diseases[SDV.CAN]Life Sciences [q-bio]/Cancermedicine.disease_causeNSCLClcsh:RC254-28203 medical and health sciences0302 clinical medicine[SDV.CAN] Life Sciences [q-bio]/CancerNon-small cell lung cancerInternal medicinemedicineOverall survivalNon–small cell lung cancerStage (cooking)neoplasms030304 developmental biology0303 health sciencesMutationTransition (genetics)business.industryKRAS mutationmedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrognosisConfidence intervaldigestive system diseases3. Good healthrespiratory tract diseasesOncology030220 oncology & carcinogenesisAdenocarcinomaOriginal ArticleKRASbusinessKras mutation
researchProduct

Variations in the prevalence of childhood asthma and wheeze in MeDALL cohorts in Europe.

2017

While there is evidence for variations in prevalence rates of childhood wheeze and asthma between countries, longitudinal, individual-level data are needed to understand these differences. The aim of this study was to examine variations in prevalence rates of childhood asthma, wheeze and wheeze with asthma in Europe. We analysed datasets from 10 MeDALL (Mechanisms of the Development of ALLergy) cohorts in eight countries, representing 26 663 children, to calculate prevalence rates of wheeze and asthma by child age and wheeze with asthma at age 4 years. Harmonised variables included outcomes parent-reported wheeze and parent-reported doctor-diagnosed asthma, and covariates maternal education…

Pulmonary and Respiratory MedicinePediatricsmedicine.medical_specialtyAllergy5Child age12Prevalencelcsh:MedicineChildhood asthma03 medical and health sciences0302 clinical medicineimmune system diseasesWheezeJournal Articlemedicine030212 general & internal medicineSleep medicineAsthmaChildhood asthmaAsthma and allergybusiness.industrylcsh:ROriginal Articlesmedicine.disease3. Good healthrespiratory tract diseasesMaternal educationCOPD and smoking030228 respiratory systemmedicine.symptombusinessDemography
researchProduct

Sex-specific and age-related seasonal variations regarding incidence and in-hospital mortality of pulmonary embolism in Germany

2020

Background Studies have reported seasonal variations regarding the incidence and the short-term mortality of pulmonary embolism (PE). The aim of this study was to identify sex-specific and age-related differences in seasonal patterns regarding hospitalisations and mortality of PE patients. Methods We analysed the impact of seasons on incidence and in-hospital mortality of male and female hospitalised PE patients in Germany (2005–2015) based on the German nationwide inpatient sample. Results The German nationwide inpatient sample comprised 885 806 hospitalisations due to PE (2005–2015). Seasonal variations of both incidence (p=0.021) and in-hospital mortality (p<0.001) were of significant ma…

Pulmonary and Respiratory MedicinePulmonary Vascular Disease7In hospital mortalitybusiness.industryIncidence (epidemiology)lcsh:Rlcsh:MedicineOriginal ArticlesSeasonalitymedicine.diseaseSex specificPulmonary embolismMale patientAge relatedFemale patientMedicinebusinessDemographyERJ Open Research
researchProduct

Mid-regional pro-atrial natriuretic peptide and copeptin as indicators of disease severity and therapy response in CTEPH

2020

Background Chronic thromboembolic pulmonary hypertension (CTEPH) leads to right heart failure. Pulmonary endarterectomy (PEA) or balloon pulmonary angioplasty (BPA) restore pulmonary haemodynamics and allow cardiac recovery. This study examined the relationship of copeptin and mid-regional pro-atrial natriuretic peptide (MR-proANP) levels to disease severity and therapy response. Methods This observational cohort study included 125 patients (55 PEA/70 BPA) who underwent treatment and completed a 6-/12-month follow-up. Biomarkers, measured at baseline, prior to every BPA and at follow-up, were compared to 1) severe disease at baseline (right atrial pressure (RAP) ≥8 mmHg and cardiac index ≤2…

Pulmonary and Respiratory MedicinePulmonary Vascular Disease7medicine.medical_specialtybusiness.industrymedicine.drug_classmedicine.medical_treatmentlcsh:RArea under the curveCentral venous pressureCardiac indexlcsh:MedicineOriginal Articlesmedicine.anatomical_structureCopeptinInternal medicineAngioplastyVascular resistancemedicineCardiologyNatriuretic peptidebusinessCohort studyERJ Open Research
researchProduct

Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4).

2015

Efficacy and safety of tiotropium+olodaterol fixed-dose combination (FDC) compared with the mono-components was evaluated in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) in two replicate, randomised, double-blind, parallel-group, multicentre, phase III trials. Patients received tiotropium+olodaterol FDC 2.5/5 μg or 5/5 μg, tiotropium 2.5 μg or 5 μg, or olodaterol 5 μg delivered once-daily via Respimat inhaler over 52 weeks. Primary end points were forced expiratory volume in 1 s (FEV1) area under the curve from 0 to 3 h (AUC0–3) response, trough FEV1 response and St George's Respiratory Questionnaire (SGRQ) total score at 24 weeks. In total, 5162 patien…

Pulmonary and Respiratory MedicineSpirometryRespimatRespiratory Medicine and Allergy1Fixed-dose combinationOBSTRUCTIVE PULMONARY-DISEASEchemistry.chemical_compoundMedicine and Health SciencesmedicineCOPDCOPDmedicine.diagnostic_testbusiness.industryInhalerOlodaterolArea under the curveOriginal ArticlesTiotropium bromidemedicine.diseaserespiratory tract diseaseschemistryAnesthesiaTRIALbusinessmedicine.drug
researchProduct

Characteristics of coronary microcirculatory function in patients with Takotsubo syndrome.

2017

Background: Takotsubo syndrome (TS) is a recently described cardiac syndrome whose pathogenesis is still unclear. We investigated the characteristics of coronary microcirculatory function in patients with TS through the analysis of the TIMI frame count (TFC) compared to normal subjects and with to subjects with microvascular angina (MA). Methods: We enrolled 71 TS patients (F:M =69:2, mean age of 65.27±9.53 years), 70 controls (F:M =34:36, mean age of 56.63±13.5 years) and 71 patients with MA, (F:M =69:2, mean age of 65.9±9.2 years). The assessment of the microcirculation was carried out through the TFC. Results: microcirculation was significantly altered in patients with TS compared with h…

Pulmonary and Respiratory MedicineTakotsubo syndromemedicine.medical_specialtybusiness.industryMicrovascular anginaMean age030204 cardiovascular system & hematologyAnterior Descending Coronary ArteryMicrocirculationPathogenesis03 medical and health sciences0302 clinical medicinemicrovascular angina (MA)Internal medicinemicrovascular functionmedicineCardiologyIn patientOriginal Article030212 general & internal medicineTIMI frame count (TFC)businessTakotsuboTIMIJournal of thoracic disease
researchProduct

Barriers and incentives for Italian paediatricians to become smoking cessation promoters: a GARD-Italy Demonstration Project

2020

Background: Paediatricians rarely devote any time to screening and treatment for parental tobacco use. The present project is part of a Global Alliance against Chronic Respiratory Diseases (GARD)-Italy Demonstration Project, aimed to increase the skills of primary care physicians and paediatricians as "promoter of smoking cessation". The aims of this study were: (I) to identify latent classes of barriers and incentives for smoking cessation counseling among paediatricians using latent class analysis (LCA); (II) to investigate risk factors for inclusion into the identified classes. Methods: In 2018, 1,500 Italian paediatricians were invited to complete an online survey on passive smoke expos…

Pulmonary and Respiratory Medicinebarriers; incentives; latent class analysis (LCA); paediatricians; smoking cessationmedicine.medical_specialtyincentivesmedicine.medical_treatmentmedia_common.quotation_subjectbarriersOriginal Article of GARD SectionLatent class analysis (LCA);Settore MED/38 - Pediatria Generale E SpecialisticaLatent class analysis (LCA)medicinepaediatricians;Multinomial logistic regressionmedia_commonbusiness.industryAddictionpaediatricianLatent class modelWork experienceincentivePassive Smoke Exposuresmoking cessationFamily medicineRespondentbarrierSmoking cessationbusinessInclusion (education)paediatricians
researchProduct